
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is a clinical-stage pharmaceutical company with a promising drug candidate, Stenoparib, for advanced ovarian cancer and a unique Drug Response Predictor technology that improves patient selection. While there are long-term development challenges and high risks, recent Q4 results showed revenue of $0.3 million and a net loss of $3.4 million, slightly better than analyst estimates. Given its potential for growth and promising fundamentals, the stock may be a high-risk, high-reward opportunity for investors.
Bears say
Allarity Therapeutics is a clinical-stage biopharmaceutical company with a focus on developing anti-cancer therapeutics using precision medicine. However, the risks associated with the development of its lead drug, Stenoparib, including potential safety and efficacy concerns, delays in regulatory approvals, and competition in the market, outweigh the potential prospects and current valuation of the company. Additionally, the company's balance sheet and liquidity pose potential risks to the attainment of its share price target.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares